23 April 2021>: Original Paper
A Single-Center Experience with Lung Transplants During the COVID-19 Pandemic
Wojtek Karolak 1ABE , Elżbieta Woźniak-Grygiel 2CE , Monika Łącka 3BC , Jacek Wojarski 1BG , Salma Ali Addo 4EF , Adith Kumaravel 4EF , Salin Khan 4EF , Reema Shinde 4EF , Ikram Mukhtar Nuur 4EF , Feven Kifle Reta 4EF , Jan Rogowski 1G , Ewa Jassem 4EG , Krystyna Pastwa 1F , Aleksandra Pałasz 1B , Nikodem Ulatowski 1B , Sławomir Żegleń 24ADG*DOI: 10.12659/AOT.929946
Ann Transplant 2021; 26:e929946
Table 2 Recipient characteristics.
Characteristics | Lung transplant 2019 before COVID-19N=12Mean±SD/n (%) | Lung transplant 2020 during COVID-19N=16Mean±SD/n (%) | p |
---|---|---|---|
50.1±12.8 | 50.6±14.5 | 0.6197 | |
Female | 4 (33.3%) | 6 (37.6%) | 0.8143 |
Male | 8 (66.6%) | 10 (62.5%) | 0.8227 |
COPD | 8 (66.6%) | 5 (31.3%) | 0.0638 |
CF | 1 (8.3%) | 2 (12.5%) | 0.7220 |
IPF | 2 (16.6%) | 2 (12.5%) | 0.7588 |
IPAH++++ | 1 (8.3%) | 3 (18.8%) | 0.4322 |
EAA | 0 (0.0%) | 1 (6.3%) | 0.3758 |
UIP | 0 (0.0%) | 2 (12.5%) | 0.2037 |
COVID | 0 (0.0%) | 1 (6.3%) | 0.3758 |
ECMO | 5 (41.6%) | 12 (75.0%) | 0.0734 |
Off pump | 6 (50.0%) | 2 (12.5%) | 0.0297 |
Conversion to ECMO | 1 (8.3%) | 2 (12.5%) | 0.7220 |
COVID-19 – corona virus disease – 2019; COPD – chronic obstructive pulmonary disease; CF – cystic fibrosis; IPF – idiopathic pulmonary fibrosis; IPAH – idiopathic pulmonary arterial hypertension; EAA – extrinsic allergic alveolitis; UIP – usual interstitial pneumonia; COVID – COVID-19 related fibrosis; ECMO – extra-corporeal membrane oxygenation; SD – standard deviation. |